Inflammation across tissues: can shared cell biology help design smarter trials?

Autor: Hosack T; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Thomas T; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Ravindran R; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Uhlig HH; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.; Biomedical Research Centre, University of Oxford, Oxford, UK.; Department of Paediatrics, University of Oxford, Oxford, UK., Travis SPL; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.; Biomedical Research Centre, University of Oxford, Oxford, UK., Buckley CD; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.; Biomedical Research Centre, University of Oxford, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.; Institute for Inflammation and Aging, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. christopher.buckley@kennedy.ox.ac.uk.
Jazyk: angličtina
Zdroj: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2023 Oct; Vol. 19 (10), pp. 666-674. Date of Electronic Publication: 2023 Sep 04.
DOI: 10.1038/s41584-023-01007-2
Abstrakt: Immune-mediated inflammatory diseases (IMIDs) are responsible for substantial global disease burden and associated health-care costs. Traditional models of research and service delivery silo their management within organ-based medical disciplines. Very often patients with disease in one organ have comorbid involvement in another, suggesting shared pathogenic pathways. Moreover, different IMIDs are often treated with the same drugs (including glucocorticoids, immunoregulators and biologics). Unlocking the cellular basis of these diseases remains a major challenge, leading us to ask why, if these diseases have so much in common, they are not investigated in a common manner. A tissue-based, cellular understanding of inflammation might pave the way for cross-disease, cross-discipline basket trials (testing one drug across two or more diseases) to reduce the risk of failure of early-phase drug development in IMIDs. This new approach will enable rapid assessment of the efficacy of new therapeutic agents in cross-disease translational research in humans.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: